Geron (GERN)
(Delayed Data from NSDQ)
$3.79 USD
+0.23 (6.46%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Geron Corporation [GERN]
Reports for Purchase
Showing records 221 - 236 ( 236 total )
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Highlights from Meeting with Management - First Site Begins Screening for Spinal Cord Trial
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
2Q10 UPDATE PHASE 2 IMETELSTAT TRIAL STARTS - hESC TRIAL HOLD LIFTED
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
R&Rs Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Initiates Phase 2 Program for Telomerase Inhibitor Imetelstat
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
1Q10 UPDATE - IMETELSTAT DATA AT AACR - SPINAL CORD TRIAL TO START 3Q10
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
4Q09 UPDATE - TELOMERASE AND REGEN MED PROGRAMS DRIVE VALUE IN 2010
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
R&Rs Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R